Europe — EMA
Ondansetron Kabi (Ondansetron Hydrochloride Dihydrate)
GNH USA supplies Ondansetron Kabi (Ondansetron), a 5-HT3 receptor antagonist for prevention of chemotherapy, postoperative and radiotherapy‑induced nausea
Request sourcing
What is Ondansetron Hydrochloride Dihydrate?
Ondansetron, the active ingredient in Ondansetron Kabi, is a 5‑HT3 receptor antagonist presented as an injectable solution for intravenous use. It prevents nausea and vomiting associated with chemotherapy, radiotherapy, and postoperative settings in adult patients.
GNH USA supplies Ondansetron Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.
What is Ondansetron Hydrochloride Dihydrate used for?
Ondansetron is a selective 5‑HT3 receptor antagonist used to control nausea and vomiting in several clinical settings.
- Chemotherapy‑induced nausea and vomiting: reduces the incidence and severity of nausea and vomiting in patients receiving emetogenic chemotherapy. - Postoperative nausea and vomiting: prevents nausea and vomiting after surgical procedures. - Radiotherapy‑induced nausea and vomiting: helps control nausea associated with radiation treatment.
What are the side effects of Ondansetron Hydrochloride Dihydrate?
Common Side Effects: - Headache: mild to moderate pain in the head. - Constipation: reduced bowel movements or hard stools. - Dizziness: sensation of light‑headedness or unsteadiness. - Fatigue: feeling unusually tired or weak. - Injection‑site reaction: erythema, pain or swelling at the IV site. - Diarrhoea: loose stools occurring after administration.
Serious or Rare Side Effects: - QT interval prolongation: potential cardiac rhythm disturbance. - Severe allergic reaction (anaphylaxis): rash, swelling, difficulty breathing. - Serotonin syndrome: agitation, hyperthermia, muscle rigidity when combined with other serotonergic agents. - Cardiac arrhythmia: irregular heartbeats that may be life‑threatening. - Hypotension: sudden drop in blood pressure. - Hepatic dysfunction: abnormal liver enzyme elevations.
What precautions apply to Ondansetron Hydrochloride Dihydrate?
Before using Ondansetron Kabi, consider the following precautions: - Cardiac risk assessment: evaluate baseline ECG and electrolyte status to mitigate QT‑prolongation risk. - Concomitant QT‑prolonging drugs: avoid or monitor closely when used with other agents that affect cardiac repolarisation. - Hepatic impairment: adjust use in patients with severe liver disease as metabolism may be reduced. - Pregnancy and lactation: use only if the potential benefit outweighs potential risk; data are limited. - Pediatric use: safety and efficacy have not been established in children for this formulation. - Store at 2‑8°C: keep refrigerated, protect from light, do not freeze or shake.
What does Ondansetron Hydrochloride Dihydrate interact with?
Ondansetron Kabi may interact with several medicines. Review the following categories:
Major Interactions (Avoid): - Other QT‑prolonging agents (e.g., quinidine, haloperidol): may increase risk of cardiac arrhythmia. - Apomorphine: can cause severe hypotension and loss of consciousness. - Serotonergic drugs (e.g., SSRIs, MAO inhibitors): risk of serotonin syndrome. - Carbamazepine: induces metabolism, potentially reducing ondansetron efficacy.
Moderate Interactions (Monitor Closely): - Dexamethasone: may enhance antiemetic effect; monitor for additive side effects. - Warfarin: possible increase in INR; check coagulation parameters. - Anticholinergic agents: may alter gastrointestinal motility; observe clinical response. - Other antiemetics (e.g., metoclopramide): combined use may increase side‑effect burden.
